Nature Reviews Gastroenterology & Hepatology

Papers
(The TQCC of Nature Reviews Gastroenterology & Hepatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Zolbetuximab treatment in metastatic gastric cancer763
Hybrid EASL Congress 2023740
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology673
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis627
Mapping neuroimmune interactions in the gut614
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed556
2023 FDA approvals in gastroenterology and hepatology462
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa392
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection386
Advancing nutrition science for global health322
The future of treating pancreatic exocrine insufficiency317
Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis309
Nomenclature of HBV core protein-targeting antivirals306
Western lifestyle, metaflammation and the cell of origin of colon cancer261
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection254
Black–White disparities across the colorectal cancer care continuum in the USA253
Large language models for clinical decision support in gastroenterology and hepatology236
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis235
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health229
Artificial intelligence and automation in endoscopy and surgery221
New understanding of hepatobiliary MRI212
Metastatic pancreatic cancer and the liver204
Food as medicine in gastrointestinal cancer therapy203
A crucial Fusobacterium nucleatum clade in colorectal cancer201
Inflammatory bowel disease in pregnancy and breastfeeding187
Lessons from incretin-based therapy in MASH and obesity186
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease179
The critical role of gut–brain signalling in eating behaviour and obesity178
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract176
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges170
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation162
Novel insights into chronic HBV infection162
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases157
Hepatocyte-derived biomarkers in alcohol-related cirrhosis156
Integrated systems approach to identify environmental factors in intestinal inflammation145
Characterizing the genomic landscape of colorectal cancer140
Implications of the evolving knowledge of the genetic architecture of MASLD139
Probiotics for preterms: sharing complex decision-making135
Estimating dietary intake from human stool DNA133
HDCA ameliorates NAFLD in mice126
Preventing the progression of cirrhosis to decompensation and death119
Medical therapy of paediatric inflammatory bowel disease118
SSRIs and depression: role of gut–brain communication117
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment116
The path to successful hepatitis C elimination in Spain107
Human intestinal B cells in inflammatory diseases103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease102
Proteases in intestinal health and disease101
Metabolic diseases in the East Asian populations101
Liver, ageing and disease97
Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus97
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management94
Phase III results for first-line treatment for metastatic colorectal cancer93
ECCO’2488
Microbiota and colorectal cancer — controlling for confounders challenges associations87
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’85
Enteric nervous system transfers stress to the gut82
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance82
Author Correction: Hepatic immune regulation and sex disparities79
The future of pathology in gastroenterology and hepatology76
GLP1R agonists in NAFLD: a promising therapy on the horizon75
HIV-associated gut microbiome influences gut mucosal immunity73
Human deskilling in medical artificial intelligence: prohibited or permissible under the EU Artificial Intelligence Act?72
Hepatic inflammatory responses in liver fibrosis70
NAFLD prevalence in older patients with T2DM70
Hepatic glucose metabolism in the steatotic liver69
Transforming the landscape of liver cancer detection and care68
SMART cancer risk prediction67
Artificial intelligence in liver cancer — new tools for research and patient management67
Liver dialysis in ACLF67
AI predicts pancreatic cancer risk65
A neurobiotic sense curbs feeding: a new frontier in gut–brain communication64
A new era in obesity management64
Nutrient sensing and small intestinal enteric neurons63
Elucidating the transmission landscape of the human microbiome63
International collaborative research to improve gallbladder cancer prevention63
MASLD as a non-communicable disease62
Nifty new tools for microbiome treatment design62
Hepatitis E virus: from innate sensing to adaptive immune responses61
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice57
Future direction of total neoadjuvant therapy for locally advanced rectal cancer57
Pushing the frontier of gut microbiome health cross-kingdom and cross-organ57
A novel pathomics signature for gastric cancer56
Cellular and molecular basis of proximal small intestine disorders53
Cathepsin S in liver fibrogenesis53
Steatosis fuels replacement liver metastases in colorectal cancer53
Bridging the gap: increasing MENA representation in MASLD clinical trials53
The steatotic liver disease burden paradox: unravelling the key role of alcohol51
Commensal fungi in intestinal health and disease50
Features of immune microenvironment associated with colorectal polyp development49
Therapeutic landscape and future direction of metastatic colorectal cancer49
Antibiotic-perturbed microbiota and the role of probiotics49
Microplastics, nanoplastics and liver disease: an emerging health concern?48
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer47
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors46
Classifying compounds as prebiotics — scientific perspectives and recommendations44
Telemedicine for hepatitis C virus treatment in opioid treatment programmes44
Long-term normothermic liver perfusion42
Author Correction: Improving IBD outcomes in the era of many treatment options41
Diet-driven microbiome restoration associated with cardiometabolic benefits41
Alcohol-free and low-strength drinks: friend or foe?40
Changes in cholera burden across Africa37
Justice, equity, diversity and inclusion in gastroenterology and hepatology36
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus35
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research35
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach34
Reply to ‘The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view’33
Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease33
Public health policies to prevent alcohol-related liver disease33
Global epidemiology of cirrhosis — aetiology, trends and predictions32
A Roadmap for the Human Gut Cell Atlas31
Gut virome dynamics: from commensal to critical player in health and disease31
Resmetirom safe for nonalcoholic fatty liver disease28
Elafibranor in primary biliary cholangitis28
ECCO’2528
New target and timing in PDAC immunotherapy?28
Positive longer-term results for efruxifermin in MASH28
Digestive Disease Week 202527
A resource for the food microbiome and its links with the human microbiome26
Intermittent fasting for NASH and HCC in mice26
Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment26
Digestive Disease Week 202326
Deciphering potential implications of dietary microplastics for human health25
Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment24
Food inequity and insecurity and MASLD: burden, challenges, and interventions24
Microplastics and nanoplastics in the human gut: from signals to standards24
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions24
Envisioning how to advance the MASH field24
HCV direct-acting antiviral therapy adherence in people who inject drugs23
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis23
Cholangiocarcinoma 2026: status quo, unmet needs and priorities23
Follow-up of SER-109 for recurrent C. difficile22
Human liver tissue in a mouse host21
IL-17A-producing CD8+ T cells in pancreatic cancer20
Optimizing sacral nerve stimulation to relieve chronic constipation20
Amitriptyline as second-line treatment for IBS in primary care settings19
Predicting mortality in cirrhosis19
Nanoparticles in NAFLD therapeutics18
Liquid biopsy combined with machine learning predicts early detection in liver disease18
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology17
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer17
Gastrointestinal health and the environment: a bidirectional relationship17
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology16
Lactylation and HCC progression16
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease16
Precision adherence support for hepatitis C treatment16
Combination treatment further extends survival16
0.097748041152954